Determination of total oncopterin, neopterin and biopterin in human urine by high performance liquid chromatography with solid phase extraction

A new, sensitive method for the determination of oncopterin, biopterin, and neopterin in human urine has been developed using SPE with 6,7‐dimethylpterin as internal standard and gradient HPLC with fluorescence detection. SPE was tested for the pre‐treatment of urine samples on different types of so...

Full description

Saved in:
Bibliographic Details
Published in:Journal of separation science 2003-06, Vol.26 (8), p.674-678
Main Authors: Tomandl, Josef, Tallova, Jaroslava, Tomandlova, Marie, Palyza, Vladimir
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biopterin
Host-tumor relations. Immunology. Biological markers
HPLC
Investigative techniques, diagnostic techniques (general aspects)
Medical sciences
Miscellaneous. Technology
Neopterin
Oncopterin
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
SPE
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new, sensitive method for the determination of oncopterin, biopterin, and neopterin in human urine has been developed using SPE with 6,7‐dimethylpterin as internal standard and gradient HPLC with fluorescence detection. SPE was tested for the pre‐treatment of urine samples on different types of sorbents (strong ion exchange resins, polar adsorbents, and reversed‐phase sorbents). RP‐SPE with subsequent evaporation of eluate has been found to be the most appropriate. The extraction efficiency exceeded 95% for all selected pterins. The extracted pterins were subsequently analyzed on a Purospher RP‐18 RP column. The LOD of oncopterin was 1.43 nmol/L of urine. The intra‐day and inter‐day imprecision at a physiological oncopterin concentration never exceeded 10%. The potential of this method was tested using urine samples of healthy volunteers and cancer patients without methotrexate therapy.
ISSN:1615-9306
1615-9314
DOI:10.1002/jssc.200301371